AMR is a crisis escalating at a rate that surpasses the current response, with urgent action needed to address the predicted 20% increase in mortality between now and 2050. 

World Antimicrobial Awareness Week (WAAW) 2024 provided a crucial platform for the REVERSE project to highlight its multifaceted approach to reducing the burden of antimicrobial resistance (AMR) in high-prevalence European healthcare settings.

Joining the global #GoBlueforAMR campaign, the REVERSE consortium ran a week-long social media initiative that showcased the essential work being carried out across all work packages and hospital sites, featuring the dedicated teams driving the project forward. 

Day 1: Laying the Foundation for Action

The campaign began with a general call to action, emphasising the urgency of the AMR crisis and the high cost it exacts on global health. The REVERSE Project Office (WP1) was featured, underscoring their vital role in coordinating the complex, multi-site work across four EU countries, ensuring effective and timely progress toward the project's goals.

Day 2: Strengthening Diagnostic Capabilities

The focus shifted to the technical heart of the project. Infections caused by carbapenem-resistant Gram-negatives represent a significant challenge to healthcare, threatening a century of progress.

WP2, led by the team from UMC Utrecht and the University of Florence, is dedicated to the rapid identification of these resistant stains using standardised methods. This work in microbiology and diagnostic stewardship is key to ensuring patients receive the right treatment as quickly as possible. 

Day 3: Curbing the Spread

Did you know that globally, only over a quarter of countries have a dedicated budget for infection prevention and control (IPC) at a national level? 

Robust IPC measures are essential to curbing AMR. WP3 is tackling this issue head-on, recognising that scaling up existing services and implementing new innovations must occur to reduce infection rates, morbidity, and mortality. Within REVERSE, IPC is a central focal point being addressed through intervention programmes, new training tools, and education for healthcare workers. 

Day 4: The Power of European Collaboration 

Combatting AMR requires collective efforts. Day 4 highlighted the power of collaboration, showcasing the hospitals participating in REVERSE from across Greece, Italy, Spain, and Romania. These country sites are the real-world laboratories where the MDS, IPC, and ABS strategies reinforce each other, proving that a holistic, collaborative approach is essential to improving patient outcomes and reducing the burden of AMR in high-prevalence settings. 

Day 5: Preserving Future Treatment 

Antibiotic stewardship (ABS) is key to fighting AMR. By using antibiotics wisely, we can preserve their effectiveness for future generations. WP4, which is focused entirely on ABS, is a core component of the REVERSE strategy. This team actively visits sites, meets and trains ABS teams and ward champions, and develops and implements new interventions - all designed as a cohesive approach to improving overall antibiotic prescribing practices. 

Day 6: Bridging Theory and Practice

The best guidelines are only effective is they are properly implemented. Day 6 provided insight into the critical role of human and organisational factors in this process. As Prof. Lauren Clack, implementation lead for the projected stated:

"Human and organisational behaviour is at the heart of many IPC and ABS activities. Our implementation science efforts focus on collaborating with and learning from the individuals and organisations that bring guidelines from theory to practise".

WP5's work is essential for ensuring the strategies developed by REVERSE are successfully adopted and sustained across the diverse healthcare settings within the consortium and participating sites. 

Day 7: The True Cost of Inaction 

The final WP featured was a sharp reminder of the financial implications of AMR. The cost is high, leading to longer hospital stays, higher medical expenditure, and increased mortality. Left unchecked, up to 1.1 billion euros are expected to be spent yearly across European countries by 2050. WP6 is focused on documenting the economic effectiveness of the REVERSE interventions. These data will be crucial for policymakers, demonstrating that investing in robust AMR strategies is not just for health imperative, but a financial necessity.

A Continued Commitment 

As WAAW drew to a close, the consortium reaffirmed its commitment to fighting AMR today, tomorrow, and every day to come. AMR is a pressing global health and socioeconomic crisis, and the work of the REVERSE project (and project's like it) highlights the necessary path forward.

We must work together to Educate, Advocate, and Act Now to tackle this looming threat.